drugset / Trial / NCT06395285
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
Timeline
- Start
- 2025-05-27
- Primary completion
- 2026-07
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DF-003 | Small molecule | 45 mg | Oral |